Biosketch / Results /

Andrew Rosenblum

Clinical Assistant Professor, Department of Pediatrics

Contact Info

718/721-9600
Andrew.Rosenblum@nyumc.org


Characteristics of Non-Opioid Substance Misusers Among Patients Enrolling in Opioid Treatment Programs: A Latent Class Analysis
Fong, Chunki; Matusow, Harlan; Cleland, Charles M; Rosenblum, Andrew. Characteristics of Non-Opioid Substance Misusers Among Patients Enrolling in Opioid Treatment Programs: A Latent Class Analysis. Journal of addictive diseases. 2015 ;34(2-3):141-150 (1768512)

Abuse and diversion of buprenorphine sublingual tablets and film
Lavonas, Eric J; Severtson, S Geoffrey; Martinez, Erin M; Bucher-Bartelson, Becki; Le Lait, Marie-Claire; Green, Jody L; Murrelle, Lenn E; Cicero, Theodore J; Kurtz, Steven P; Rosenblum, Andrew; Surratt, Hilary L; Dart, Richard C. Abuse and diversion of buprenorphine sublingual tablets and film. Journal of substance abuse treatment. 2014 Mar 3;47(1):27-34 (970132)

Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes
Matusow, Harlan; Dickman, Samuel L; Rich, Josiah D; Fong, Chunki; Dumont, Dora M; Hardin, Carolyn; Marlowe, Douglas; Rosenblum, Andrew. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of substance abuse treatment. 2013 May -0;44(5):473-480 (264242)

Buprenorphine-naloxone maintenance following release from jail
Lee, Joshua D; Grossman, Ellie; Truncali, Andrea; Rotrosen, John; Rosenblum, Andrew; Magura, Stephen; Gourevitch, Marc N. Buprenorphine-naloxone maintenance following release from jail. Substance abuse. 2012 ;33(1):40-47 (150570)

Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol
Rosenblum, Andrew; Cruciani, Ricardo A; Strain, Eric C; Cleland, Charles M; Joseph, Herman; Magura, Stephen; Marsch, Lisa A; McNicholas, Laura F; Savage, Seddon R; Sundaram, Arun; Portenoy, Russell K. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. Journal of opioid management. 2012 Nov -1;8(6):369-382 (249352)